AAD 2026 to Showcase Advances in Psoriasis Management

Experts anticipate new data on oral therapies and comorbidity treatment

Mar. 13, 2026 at 6:49pm

Got story updates? Submit your updates here. ›

The upcoming American Academy of Dermatology conference in Denver is expected to feature groundbreaking research on innovative oral psoriasis treatments, including icotrokinra and TYK2 inhibitors like zasocitinib and envudeucitinib. Experts are also eager to see data on combination therapies that address both skin manifestations and broader health challenges faced by psoriasis patients, such as obesity, diabetes, and cardiovascular disease.

Why it matters

Psoriasis is a chronic, inflammatory skin condition that affects millions worldwide. Advances in treatment options, particularly oral therapies and combination approaches, have the potential to significantly improve outcomes and quality of life for those living with psoriasis.

The details

According to Dr. Tina Bhutani, a leading dermatologist, the AAD 2026 conference will showcase some of the most exciting developments in psoriasis management in recent years. This includes new data on oral treatments like icotrokinra and cutting-edge TYK2 inhibitors, as well as studies on combination therapies that address both the skin manifestations and broader health challenges associated with psoriasis, such as the use of ixekizumab with tirzepatide.

  • The AAD 2026 conference will take place in Denver, Colorado.
  • The conference is scheduled for March 13-15, 2026.

The players

Tina Bhutani, MD, MAS

A leading dermatologist who specializes in psoriasis and is anticipating the exciting new data to be presented at the AAD 2026 conference.

Got photos? Submit your photos here. ›

What they’re saying

“Groundbreaking studies on combination therapies will also be presented, such as the use of ixekizumab with tirzepatide, which may offer new hope for managing both psoriasis and psoriatic arthritis.”

— Tina Bhutani, MD, MAS, Dermatologist (medscape.com)

What’s next

Dermatologists and researchers will closely follow the presentations and discussions at the AAD 2026 conference, as the new data on oral therapies and combination treatments could lead to significant advancements in the management of psoriasis.

The takeaway

The upcoming AAD 2026 conference in Denver promises to showcase some of the most exciting developments in psoriasis treatment, including innovative oral therapies and combination approaches that address both the skin manifestations and broader health challenges faced by patients. These advancements have the potential to greatly improve outcomes and quality of life for those living with this chronic, inflammatory condition.